CAPE TOWN, SA / ACCESSWIRE / August 21, 2020 / WUHAN GENERAL GROUP, INC. (OTC Pink:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is delighted to share the following corporate update:

Supply Chain, Operations and Covid-19:

August 18th, South Africa transitioned from level 3 lockdown to level 2 with many restrictions being lifted amid its battle with coronavirus. This is great news for the Company and the country, as it enables more flexibility in managing supply chain risk and disruption. Coronavirus has had a colossal impact on almost all businesses in South Africa and around the world where supply chain challenges were felt from the global spread of COVID-19. With many restrictions being lifted, conditions should approach normalcy in the coming months.

Visits:

Wuhan CEO Jeff Robinson and Willem Jonker, Head of Wuhan Cannabis Production are scheduling a visit to the Tsime Pharmaceuticals site in Lesotho where the Company will cultivate 3 hectares of medicinal grade cannabis on a farm with a land area covering 32 hectares (or 80 acres). With its license, the Company will grow, extract and process medicinal cannabis on-site, a key element in driving Wuhan's medicinal cannabis research and the manufacturing of CBD by-products. Both Mr. Robinson and Mr. Jonker will be tested for Coronavirus and will need to test negative in order to make the 4-hour flight to the Kingdom of Lesotho from Cape Town.

Mr. Robinson and other Wuhan team members visited Edelweiss Laboratories on August 19th to finalize updated and go-to-market formulations for Dr. AnnaRxtm Skincare, Haircare and Oral care Lines.

Mr. Robinson is scheduled to visit the beverage manufacturing partner CaffeLuxe in the coming weeks to place their first significant order for the MedspressoTM range for sale through online e-commerce and select retail outlets.

Sales:

The company has been selling its MedspressoTM Tanzanian Peaberry CBD Coffee online in Cape Town. Customer feedback has been extremely positive.

New Corporate Website:

The company is launching a brand new revamped website under the newly created corporate name M2Bio Science. The website offers quick and easy access to essential information and offers a more comprehensive understanding of the Company's vision, products and innovations. The website also has an extensive investor section with updated company news and events, financial and stock information, filings and corporate governance information. The new website is located at the new address: https://m2bio.co

YouTube Channel:

Please visit the M2Bio Sciences YouTube channel. The Company is using the following platform for business communication and to improve and augment their public relations efforts. Here are some elements posted and many more to come in the near future.

Product videos
Trade and industry videos
Company executive interview videos
New partnership videos

‘'Coronavirus slowed everybody down without a doubt. It did however give us lots of time to reflect, improve and plan much more efficiently and effectively. I look forward to sharing a boatload of rousing news in the near-term including our work to date in the psychedelics space. Stay tuned, we're just getting started!''

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer's and Parkinson's. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".

For further information:

Publicly traded company (OTC Pink: WUHN)
Website: https://m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/M2BIO

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc.

ReleaseID: 602764

"The Algerian Hoax" is the Fifth Novel in Croft's Popular Michael Vaux Spy Series

TORONTO, ON / ACCESSWIRE / August 21, 2020 / Author Roger Croft is pleased to announce the launch of his newest book, "The Algerian Hoax." The book is the fifth release in Croft's popular Michael Vaux spy novel series.

To learn more about "The Algerian Hoax," which can be purchased on Amazon, Barnes & Noble and at Books a Million, please check out https://rogercroft.com/the-algerian-hoax/.

As Croft noted, fans of the Michael Vaux series should enjoy his latest spy novel, which starts off with top officials at MI6, Britain's intelligence agency, suspecting that one of their senior operatives has betrayed them. Michael Vaux comes under close scrutiny by Secret Service Intelligence in the wake of anonymous charges of betrayal and double-dealing.

Readers of "The Algerian Hoax" will be on the edge of their seats as they follow along with Vaux as he is ordered to fly to Marseille as an undercover agent to probe an alleged terrorist plot; as Croft noted, this is all part of the MI6's top brass' plan to entrap Vaux in an anti-terrorist operation.

Even though Croft released "The Algerian Hoax" just recently, it is already getting a lot of positive attention from fans of the Michael Vaux series and spy novels in general, as the following excerpt from the book makes clear:

"In the distance he could hear the subdued rumblings of the late-night traffic around the harbor. The narrow, darkened streets were deserted except for couples who seemed reluctant to go home and listless young men hawking drugs to any aimless punter who looked interested or bored. Vaux looked up at the shabby, shuttered building. Nothing had changed since his earlier reconnaissance.

"But then he saw it: through a sash window on the third floor-a glimmer of light that projected upwards to a yellowed ceiling. He stood on the other side of the street and watched. There was no movement and no hint of any activity. He walked through the small cobbled front garden towards the door: withered plants in old clay flower pots served as sentries to the narrow entrance, painted blue many moons ago, faded and blistered by the hot sun. Vaux looked for a bell push. Suddenly the door opened.

"A tall thin man in a long, striped cotton thobe, gave a slight bow and gestured with his arm for Vaux to enter. In the sepulchral blue-tiled foyer, the man silently gestured again towards the narrow staircase. Vaux nodded as the old man lightly brushed past him to climb the stairs and presumably to the man Craw had described as the key contact in what he called the ‘multinational effort' to support MI6's Operation Mascara.

"A light knock at the door, followed by two more in rapid succession. He saw a dark, bulky figure sitting at a small desk at the far side of the room. An anglepoise lamp threw a round, bright light on the leather surface and effectively obscured the man's face in the surrounding gloom.

"‘Ah, Westropp! You don't know me but I've heard a lot about you! My assistant, Mustafa, had noticed you loitering in front of the house. So all is well.'"

About Roger Croft:

Roger Croft was born in Bushey, Hertfordshire, England. Following national service, Croft landed his first job in journalism with London's Daily Mail where he worked on the City (financial) staff under legendary editor Patrick Sergeant, who taught him the basics of popular journalism. Croft went on to work at a number of other publications and enjoyed a long career before switching gears to write spy novels. Since he quit the grind of daily journalism, Croft has toured the world for novel ideas. For more information, please visit http://www.rogercroft.com.

Contact:

Roger Croft
rcroft@sympatico.ca
416 923 9389

SOURCE: Roger Croft

ReleaseID: 602762

In the New Article, Deloney Shared Common Mistakes that All Landlords Should Try to Avoid

LOS ANGELES, CA / ACCESSWIRE / August 21, 2020 / Winston Deloney, a real estate investor and entrepreneur based in Chicago, Illinois, is pleased to announce that he was recently featured in an article on the Space Coast Daily website.

To read the new article, which is titled "Real Estate Expert Winston Deloney Shares Common Mistakes All Landlords Should Avoid" in its entirety, please check out https://spacecoastdaily.com/2020/08/real-estate-expert-winston-deloney-shares-common-mistakes-all-landlords-should-avoid/.

As Deloney told the author of the article, real estate investors who own rental properties are also typically the landlord. For people who are new to the world of real estate investing, this can be a challenging time as they learn to navigate the ins and outs of their role as landlord.

In order to help new landlords, as well as established ones who are facing issues with their tenants, Deloney was happy to share some common mistakes that all landlords should avoid.

For example, Deloney said that not being strict with tenant screenings is a common problem, especially with newbies to the landlord role. In order to quickly rent out housing, it may be tempting to fill the units with anyone who walks in the door.

As Deloney noted, acting in haste can actually end up costing landlords a lot of money in the long run.

"Taking the time and effort to carefully screen your tenants allows you to weed through ones who may not have stable jobs, adequate income, or who may have a history of things like property damage," he said.

Another common issue that can come back to haunt new landlords is not being knowledgeable about rental, tenant and landlord laws. While it may seem like a tall order to be up on these types of laws, Deloney said studying them will help landlords to know when they can legally do, what their tenants can legally do and what protocols must be followed.

Trying to avoid hiring professionals to complete needed tasks on the property is another common mistake that many landlords make, Deloney said. Even those who are great at DIY projects can fall behind in their work, and the property can suffer as a result.

"Landlords may be hesitant to want to call in professionals, because they think of the cost. But as problems escalate without being properly solved, they'll become more and more costly to fix," he said in the article.

About Winston Deloney:

Winston Deloney is a Chicago, IL based real estate investor, passionate entrepreneur, and a self-proclaimed foodie. To learn more, follow Winston Deloney on his Facebook page here: https://www.facebook.com/TheWinstonDeloney/.

Contact:

WInston Deloney
thewinstondeloney@gmail.com
773-453-5132

SOURCE: Winston Deloney

ReleaseID: 602760

MIDDLETOWN, NY / ACCESSWIRE / August 21, 2020 / The Board of Directors and Orange Bank & Trust Company President and CEO Michael Gilfeather are pleased to announce that Carl Capuano has joined the Bank as First Vice President, Senior Commercial Loan Officer.

"We are very pleased to have Carl join the team," said Michael Gilfeather. "In his new role, Carl will handle some of the Bank's larger and more complex relationships, as well as originating and developing relationships primarily within the Bank's Orange County market. Carl's local market knowledge along with his extensive experience as a Commercial and Industrial Lender with a focus in Healthcare, Manufacturing, Distribution, Not-for-Profit, as well as, Investment Real Estate and Construction will be particularly valuable as we continue to expand our leading business banking position in the entire Hudson Valley market."

Mr. Capuano has more than 35 years of Commercial Lending experience most recently as Chief Lending Officer for Lincoln 1st Bank. Prior to Lincoln 1st, Carl worked at Ulster Savings, and spent 20 years at Sterling National Bank serving in various commercial banking and senior management positions including Senior Commercial Lender.

Mr. Capuano earned his bachelor's degree from Fordham University and his master's from Pace University. He is a current or former board member of St. Thomas Aquinas College, the Rockland YMCA, Salvation Army of Rockland County, Westchester March of Dimes and People to People of Rockland County.

About Orange Bank & Trust Company

Orange Bank & Trust Company is an independent bank that began with the vision of 14 founders over 125 years ago. It has grown through conservative banking practices, ongoing innovation and an unwavering commitment to its community and business clientele to more than $1 billion in total Assets. In recent years, Orange Bank & Trust has added branches in Rockland and Westchester Counties and acquired Hudson Valley Investment Advisors, a wealth management company.

For further information:

Candice Varetoni
AVP Marketing Officer
cvaretoni@orangebanktrust.com
Phone: (845) 341-5043

SOURCE: Orange County Bancorp, Inc.

ReleaseID: 602752

MANSFIELD, MA / ACCESSWIRE / August 21, 2020 / Take the next step to live the life you've dreamed of, achieve your goals and harness your personal power with Billy G Life Coaching.

Born and raised in Mansfield, MA, Billy always knew he wanted to pursue a career in which he could help people. Although he didn't know exactly what that path may be, he was clear in his desire to make a difference in the lives of others. He got his first motivational speaking opportunity as early as his senior year of highschool when after having witnessed him give another speech, the school's soccer coach invited him to speak to the struggling team, hopeful that he may be able to motivate the players to turn the season around. The intended result was accomplished; after Billy spoke to the team, they would go on to produce a seven game winning streak, get out of their losing slump and eventually make it into the semi-finals. While Billy was thrilled at the impact he had been able to have on the team, he still didn't have a clear vision for how motivational speaking could fit into his life.

The next year he enrolled in Bridgewater State University where he elected to study chemistry. Although he enjoyed his courses, he found himself continuously drawn to psychology and matters of the mind. Realizing the potential to help people reset their mindset through therapy, he switched his major to psychology and went on to graduate with a degree.

Shortly after graduating, Billy experienced a series of events that left him feeling lost and hopeless. When his relationship ended, his grandmother passed away, family struggles and the pressures of work seeming insurmountable, Billy found himself alone on a Saturday evening, mind whirling about what his next steps may be. Looking for distraction or perhaps divine intervention, Billy googled Tony Robbins. A quick search turned up a course that Tony Robbins was hosting that would train others in the same life coaching techniques that Robbins utilized daily. It was as if something had clicked in Billy's mind and he knew instantly that this was the path he was meant to pursue.

Although he was passionate about the learning he was undergoing and the skills he was obtaining through Tony Robbins' training, Billy still felt as though something was missing from his life. When a stranger, now his best friend, MJ, found him in the gym, emotional, broken and yet still trying to rep out squats and power through, he invited him to church; an invitation that would alter the course of his life forever. Through going to church with MJ, Billy found God and realized that this had been the missing puzzle piece all along. As soon as he began to turn to God for guidance, instead of relying on himself, things began to fall into place.

Today, Billy's passions are multifaceted, he is a Strategic Intervention Life Coach, motivational speaker and therapeutic mentor, all offerings exist under the umbrella of Billy G Life Coaching. When offering life coaching services to clients, Billy employs Strategic Intervention, a method that encourages people to take immediate and strategic action in their lives to pursue their goals, meet their needs and achieve a more fulfilling lifestyle. Billy is confident that by shifting your mindset, you can reprogram your thinking to unlock your personal growth potential and find success in all areas of your life. After a client has begun their personal growth journey, they are ready to discover the personal power that lies within. Billy provides clients with the tools and strategies to harness that personal power for optimal success.

As Billy's motivational speaking abilities have developed over the years, he found himself back in the same highschool soccer locker room, at the behest of the same soccer coach, nearly a decade later. Billy gave another rousing speech to the team, who would go on to win the championship game. Billy does not credit himself for their win, rather he shares that he simply gave them the tools to unlock what was within them all along. A taste of Billy's motivation can be accessed by anyone, through his YouTube channel Once a Week with Billy G.

When Billy is not life coaching or speaking, he is passionate about working with underserved communities through providing one on one therapeutic mentorship to kids ranging from 5 to 18. Billy's methods with children differ from his life coaching tactics as he seeks to meet the kids wherever they are and establish a comfortable environment that encourages kids to open up and work through problems in a safe space. Billy is flexible in his approach, sharing that one day he may spend a session drawing with a young child and discussing their homelife, while the next day he may head to the courts for a round of basketball with a teen, simply to get them talking.

Whether he is coaching, speaking or mentoring kids, it is clear that Billy is living out his childhood goal of helping others. According to Billy, this is only the beginning, and he looks forward optimistically to the ways in which he will grow his coaching business in the years to come and continue to help as many people as possible with his motto: "No Doubt Absolute Faith."

CONTACT:

Contact Name: Billy Giannouloudis
Business Name: Billy G Life Coaching
Address: 1410 West St, Mansfield MA 02048
Phone Number: 774-238-2094
Website Link: https://billyglifecoaching.com/
Send Email

SOURCE: Billy Giannouloudis

ReleaseID: 602645

LOS ANGELES, CA / ACCESSWIRE / August 21, 2020 / Compare-autoinsurance.org (http://compare-autoinsurance.org/) is a top auto insurance brokerage website, providing car insurance quotes online from trustworthy agencies all over the United States. This website released an online guide that presents the most valuable car insurance discounts and how to get them.

Car insurance discounts make a policyholder's life easier. The good news is that there are many discounts available on the market. But each company has its own rules for obtaining them. So, always ask the insurer to provide a list with offered discounts and requirements. Furthermore, drivers can check if they qualify for some discounts when using online quotes. Visit http://compare-autoinsurance.org to get free car insurance quotes from top-rated insurance companies all over the United States.

Bundling policies. When combining multiple insurance types or insuring multiple vehicles under the same contract, the policyholder will get a discount. The value of the discount varies by the insurance company. Generally, the more business the policy holder brings to the company, the bigger the discount will be. In some cases, the discount can be as high as 20%. In the long term, the policyholder can save thousands of dollars. Most online questionnaires highlight the bundling options and how much can be saved.
Defensive driving discounts. Drivers can get an insurance discount for studying well and passing defensive driving exams. However, they will get discounts only if they graduate in approved courses. Insurance companies offer this type of course, so always check first if the current provider offers defensive driving courses. When getting online quotes, users are usually asked if they have participated in defensive driving programs or they are willing to participate.
Safety gear discount. Having the right safety equipment can trim insurance costs. The list of eligible items for this discount includes immobilizers, lane departure systems, hi-quality airbags and seatbelts, head and kneed protection. Each company may use a different name for this discount/ When getting online quotes, drivers are asked if the car has safety or anti-theft devices installed.
Low mileage discount. Being less exposed to accidents will significantly lower insurance costs. The rule for obtaining this discount is simple: drive less than a certain number of miles. The average annual mileage is 12.000. Anything below that will qualify the driver for a discount. Online questionnaires ask the user to approximate the annual mileage or daily mileage.

"Insurance companies offer a great number of discounts. Drivers should check for how many they qualify and ask for a price update", said Russell Rabichev, Marketing Director of Internet Marketing Company.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

For more information, please visit http://compare-autoinsurance.org

CONTACT:

Company Name: Internet Marketing Company
Person for contact Name: Gurgu C
Phone Number: (818) 359-3898
Email: cgurgu@internetmarketingcompany.biz
Website: https://compare-autoinsurance.org/

SOURCE: Internet Marketing Company

ReleaseID: 602733

Completion of Any Acquisition Remains Subject to, Among Other Things, the Negotiation and Execution of a Definitive Agreement and Satisfaction of Closing Conditions

LAFAYETTE, LA / ACCESSWIRE / August 21, 2020 / RedHawk Holdings Corp. (OTC PINK:SNDD) ("RedHawk" or the "Company"), a diversified holding company primarily engaged in sales and distribution of medical devices, announced today that its wholly-owned subsidiary, RedHawk Pharma, LLC, has been in discussions to potentially acquire certain cannabis assets including licenses to grow, manufacture and sell in the State of Oklahoma, with an anticipated initial focus on "craft" cultivation and distribution of product.

The Company anticipates a short but comprehensive due diligence period. A closing, if any, is expected to occur before December 31, 2020 and is contingent upon, among other things, approval by RedHawk's board of directors, the negotiation, acceptance and execution of a final definitive purchase agreement, acceptance and approval by the board of directors and the shareholders of the seller, satisfactory completion of legal and financial due diligence, RedHawk obtaining the required amount of acquisition financing, and the obtainment of all necessary consents and approvals of any third parties.

Accordingly, RedHawk cannot provide any assurance that a definitive agreement will be reached on acceptable terms or at all, that due diligence will be satisfactory, that the required acquisition financing will be obtained by RedHawk on acceptable terms or at all, or that the acquisition will ultimately be completed in any particular time frame or at all.

About RedHawk Holdings Corp.

RedHawk Holdings Corp. is a diversified holding company which, through its subsidiaries, is engaged in the sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells the Sharps and Needle Destruction Device (SANDD™), WoundClot Surgical – Advanced Bleeding Control, and the Carotid Artery Digital Non-Contact Thermometer. Through our United Kingdom based subsidiary, we manufacture and market branded generic pharmaceuticals. RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full-body x-ray scanner. For more information, please visit: http://www.redhawkholdingscorp.com

Cautionary Statement Regarding Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are all statements other than statements of historical fact. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. The words "anticipate," "may," "can," "plans," "believes," "estimates," "expects," "projects," "targets," "intends," "likely," "will," "should," "to be," "potential" and any similar expressions are intended to identify those assertions as forward-looking statements.

Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results, including any potential completion of the acquisition of the cannabis assets described herein, may differ materially from that projected or suggested herein due to certain risks and uncertainties including, but not limited to, the negotiation, acceptance and execution of a final definitive purchase agreement, acceptance and approval by the board of directors and the shareholders of the seller, satisfactory completion of legal and financial due diligence, RedHawk obtaining the required amount of acquisition financing, and the obtainment of all necessary consents and approvals of any third parties. In evaluating forward-looking statements, you should consider the various factors which may cause actual results to differ materially from any forward-looking statements including those listed in the "Risk Factors" section of our latest 10-K report. Further, the Company may make changes to its business plans that could or will affect its results. Investors are cautioned that the Company will undertake no obligation to update any forward-looking statements.

Company Contact:

G. Darcy Klug, Chairman and CFO
(337) 269-5933
darcy.klug@redhawkholdingscorp.com

Philip C. Spizale, CEO
(337) 269-5933
philip.spizale@redhawkholdingscorp.com

Investor Relations:
Stephanie Prince, Managing Director
PCG Advisory
(646) 762-4518
sprince@pcgadvisory.com

Media Contact:
Valerie Allen
Valerie Allen Public Relations
(310) 382-7800
valerie@valerieallenpr.com

SOURCE: RedHawk Holdings Corp.

ReleaseID: 602688

LEESBURG, VA / ACCESSWIRE / August 21, 2020 / Quantum Computing Inc. (OTCQB:QUBT) (QCI), a technology leader in quantum-ready applications and tools, and only public pure play in the quantum computer space, has been invited to present at LD Micro's LD 500 virtual institutional investor conference being held on September 1-4, 2020.

CEO of QCI, Robert Liscouski, is scheduled to present on Tuesday, September 1, at 3:20 p.m. Eastern time and participate in virtual one-on-one meetings with institutional analysts and investors throughout the day.

The presentation will be webcast live and available for replay here and via the investor relations section of the company's website at quantumcomputinginc.com.

Management will discuss the company's official commercial launch of its SaaS-based Mukai™ quantum computing software execution platform that enables developers to create applications that benefit from quantum advantage without having to know anything about the backend connections to cloud-based quantum computers.

Mukai is the first and only software platform to achieve best-in-class performance and deliver performance advantages using quantum computing software tools running on classical computers. The results of this breakthrough in performance were recently published in a benchmark study.

QCI is looking to take advantage of the rapidly growing market for quantum computing which is climbing at a 23.2% CAGR and expected to reach $9.1 billion by 2030, according to Tractica.

The LD 500 is one of the nation's largest independent conferences for micro-cap companies, with over 300 names presenting. The conference will also feature variety of speakers and panelists discussing topics of interest to investors and issuers.

To schedule a virtual one-on-one meeting with Quantum Computing, you may submit your request to register for the conference here or contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events.

View QCI's LD Micro profile here: www.ldmicro.com/profile/QUBT

Profiles powered by LD Micro – News Compliments of Accesswire

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, LD 500, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe. For more information about LD Micro, go to www.ldmicro.com/events.

About Quantum Computing Inc.

Quantum Computing Inc. (QCI) is focused on developing novel applications and solutions utilizing quantum and quantum-ready computing techniques to solve difficult problems in various industries. The company is leveraging its team of experts in finance, computing, security, mathematics and physics to develop commercial applications for industries and government agencies that will need quantum computing power to solve their most challenging problems. For more information about QCI, visit www.quantumcomputinginc.com.

Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. Those statements include statements regarding the intent, belief or current expectations of Quantum Computing ("Company"), and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.

The Company undertakes no obligation to update or revise forward-looking statements to reflect changed conditions. Statements in this press release that are not descriptions of historical facts are forward-looking statements relating to future events, and as such all forward-looking statements are made pursuant to the Securities Litigation Reform Act of 1995. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," "aim to", or variations of these or similar words, identify forward-looking statements. These risks and uncertainties include, but are not limited to, those described in Item 1A in the Company's Annual Report on Form 10-K, which is expressly incorporated herein by reference, and other factors as may periodically be described in the Company's filings with the SEC.

Mukai™ and QuOIR™ are trademarks of Quantum Computing Inc. Intel® is a trademark of Intel Corporation.

Company Contact
Robert Liscouski, CEO
Tel (703) 436-2161
info@quantumcomputinginc.com

Investor & Media Relations Contact
Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact

SOURCE: Quantum Computing Inc.

ReleaseID: 602709

VenoValve Patients Continue to Show Significant Improvement at One Year

IRVINE, CA / ACCESSWIRE / August 21, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that two additional VenoValve patients from HJLI's first-in-man, clinical study in Colombia have now reached the one-year milestone following VenoValve surgery, and that chronic venous insufficiency ("CVI") has significantly improved in both patients when compared to pre-surgery levels. For the two additional patients that are now one-year post VenoValve surgery, including one patient that is 86 years old, reflux (the backwards flow of blood) has improved an average of 62%, Venous Clinical Severity Scores ("VCSSs") have improved an average of 42%, and pain, as measured on a visual analog scale ("VAS") improved an average of 79%.

Eight VenoValve patients have now completed the one-year first-in-human trial. For the seven patients with working VenoValves, reflux, VCSS, and VAS are 57%, 55%, and 64% respectively, at one year, compared to pre-surgery levels. On average, the seven patients showed an 8 point improvement in VCSS scores at one year, compared to pre-surgery levels. In one patient, the VenoValve stopped working (occluded) after 90 days due to the patient's failure to continue to take the appropriate dosage of anticoagulation medication.

The improvements in VCSS scores is significant and indicates that VenoValve patients who had severe CVI pre-surgery, now have mild CVI or the complete absence of disease at one-year post surgery. VCSS scores are commonly used to objectively assess clinical outcomes in the treatment of venous disease, and include ten characteristics including pain, inflammation, skin changes such as pigmentation and induration, the number of active ulcers, ulcer duration and ulcer size. None of the VenoValve patients experienced ulcer recurrence during the one-year period post-surgery. Venous ulcer recurrence is common for patients suffering from deep venous CVI.

Dr. Marc H. Glickman, Hancock Jaffe's Senior Vice President and Chief Medical Officer stated, "An 8 point average decease in VCSS scores after one year post-surgery is a significant improvement that will garner a lot of attention among the vascular community. It is extremely gratifying when as a result of the VenoValve, the pain score, that is graded on a scale, of one to ten, goes from an 8 pre-surgery to 1 at one year post VenoValve surgery, for an 86 year old patient that has suffered from severe CVI for more than 30 years."

CVI occurs when the valves in the veins of the leg are injured or destroyed, causing blood to flow backwards, which is known as reflux. Reflux results in increased venous pressure (venous hypertension), damage to the veins, and results in the pooling of blood in the lower leg. Deep venous CVI is a serious condition, often resulting in debilitating pain, swelling, and open sores (venous ulcers) on the lower leg. HJLI has implanted VenoValves in 11 patients over the course of a year as part of its first-in-man, Colombian study, which is the pre-cursor to the U.S. pivotal trial. Data is being reported today for the first eight VenoValve patients to reach the critical, one-year milestone. The eight VenoValve patients that are one-year post surgery have now completed the first-in-man, clinical study and this phase of the VenoValve study will conclude in December when the three remaining patients are all one year post surgery.

Next steps for the VenoValve include the continued monitoring of the remaining three VenoValve patients in Colombia, the completion of a series of functional tests mandated by the U.S. Food and Drug Administration ("FDA"), and the filing of an IDE application with the FDA seeking approval to begin the U.S. pivotal trial, which HJLI expects to file in the first quarter of 2021.

Approximately 2.4 million people in the U.S. suffer from CVI due to reflux in the deep venous system. Estimates indicate that direct medical costs from CVI in the U.S. exceed $38 Billion a year. There are currently no FDA approved devices, or effective treatments for deep venous CVI.

About Hancock Jaffe Laboratories, Inc.

Hancock Jaffe Laboratories (NASDAQ: HJLI) specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. Hancock Jaffe currently has two lead product candidates: the VenoValve®, a porcine based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery. Hancock Jaffe has a 20-year history of developing and producing FDA approved medical devices that sustain or support life. The current management team at Hancock Jaffe has been associated with over 50 FDA or CE marked medical devices. For more information, please visit HancockJaffe.com.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the performance of the new board members described herein) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

SOURCE: Hancock Jaffe Laboratories, Inc.

ReleaseID: 602710

AUSTIN, TX / ACCESSWIRE / August 21, 2020 / AYRO, Inc. (NASDAQ:AYRO), a manufacturer of light-duty, urban and short-haul electric vehicles (EVs), today announced an initial order from Club Car for nine Club Car 411 electric vehicles to serve a military medical campus in the Northeast United States. This is the first Club Car 411 deployment that will serve a major medical center. The initial order has already been deployed and includes an opportunity for additional follow-on orders.

With this order, AYRO and Club Car are supporting the customer's goal to replace the facility's existing gas-powered vehicles with quieter, emissions-free alternatives that can achieve the diverse operational requirements of a medical campus. The Club Car 411 EVs will be used by various crews to perform facility and campus maintenance services and installations year-round and to transport a wide variety of equipment and parts.

Rod Keller, Chief Executive Officer of AYRO, Inc., commented, "We are pleased to announce this order, and are particularly proud that our zero-emissions Club Car 411 vehicles will be deployed on this campus to serve our recovering military personnel. Given our ability to deliver purpose-built solutions and deliver them quickly, medical facilities are just one of the many different venues and types of campuses that can benefit from the environmental, operational and economic solutions that the Club Car 411 provides. With over 6,000 hospitals in the U.S.(aha.org), we are excited to deploy our first all-electric trucks and vans into this market."

Club Car acts as AYRO's exclusive 411 distribution partner. A Club Car dealer closed the transaction and will provide service and maintenance support.

About AYRO, INC.

Texas-based AYRO, Inc. designs and delivers compact, emissions-free electric fleet solutions for use within urban and short-haul markets. AYRO's vehicles are capable of accommodating a broad range of commercial requirements. AYRO was founded in 2017 by entrepreneurs, investors, and executives with a passion to create sustainable urban electric vehicle solutions for Campus Management, Last Mile & Urban Delivery and Closed Campus Transport. For more information, visit: www.ayro.com.

About Ingersoll Rand and Club Car

Ingersoll Rand Inc. (IR), driven by an entrepreneurial spirit and ownership mindset, is committed to helping make life better. We provide innovative and mission-critical industrial, energy, medical and specialty vehicle products and services across 40+ respected brands designed to excel in even the most complex and harsh conditions where downtime is especially costly. Our employees connect to customers for life by delivering proven expertise, productivity and efficiency improvements. For more information, visit www.IRCO.com.

With over 60 years of experience of innovation and design in producing small-wheel vehicles, Club Car is a leading manufacturer of gas and electric golf, utility and personal transportation vehicles. Founded in 1958, the Club Car product portfolio has grown to include much more than golf cars, now encompassing vehicles for commercial and consumer markets, built with an uncompromised desire for superior performance. As an industry leader in electrification and sustainability, Club Car is proud to be on the forefront of environmentally responsible Zero Emission Vehicle (ZEV) technologies. For more information, visit www.clubcar.com

Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would" and their opposites and similar expressions are intended to identify forward-looking statements and include the intended use of net proceeds from the registered direct offering. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: AYRO has a history of losses and has never been profitable, and AYRO expects to incur additional losses in the future and may never be profitable; the market for AYRO's products is developing and may not develop as expected; AYRO's limited operating history makes evaluating its business and future prospects difficult and may increase the risk of any investment in its securities; AYRO may experience lower-than-anticipated market acceptance of its vehicles; developments in alternative technologies or improvements in the internal combustion engine may have a materially adverse effect on the demand for AYRO's electric vehicles; the markets in which AYRO operates are highly competitive, and AYRO may not be successful in competing in these industries; AYRO relies on and intends to continue to rely on a single third-party supplier for the sub-assemblies in semi-knocked-down for all of its vehicles; AYRO may become subject to product liability claims, which could harm AYRO's financial condition and liquidity if AYRO is not able to successfully defend or insure against such claims; increases in costs, disruption of supply or shortage of raw materials, in particular lithium-ion cells, could harm AYRO's business; AYRO will be required to raise additional capital to fund its operations, and such capital raising may be costly or difficult to obtain and could dilute AYRO stockholders' ownership interests, and AYRO's long term capital requirements are subject to numerous risks; AYRO may fail to comply with environmental and safety laws and regulations; and AYRO is subject to governmental export and import controls that could impair AYRO's ability to compete in international market due to licensing requirements and subject AYRO to liability if AYRO is not in compliance with applicable laws. A discussion of these and other factors with respect to AYRO is set forth in the Quarterly Report on Form S-10 for the quarterly period ended June 30, 2020, filed by AYRO on August 14, 2020. Forward-looking statements speak only as of the date they are made and AYRO disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR RELATIONS CONTACTS:

Darrow Associates
Jordan Darrow
512-551-9296
jdarrow@darrowir.com

Darrow Associates
Peter Seltzberg
516-419-9915
pseltzberg@darrowir.com

Media

Liz Crumpacker
Media Relations Contact
ayro@antennagroup.com

SOURCE: AYRO, Inc.

ReleaseID: 602745